Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11553055 | 0.91 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL11550471 | 0.89 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL13609636 | 0.89 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| Bromide SCHEMBL4266547 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL3718211 | 0.84 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL23000479 | 0.84 | MAPT (0.53) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL2374034 | 0.84 | TSHR (0.52) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL1192875 | 0.84 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL10892998 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TDP1MAPTMEN1 | |
| SCHEMBL1799181 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TDP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0010426-A1 | Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
| US-20170327510-A1 | PHTHALOCYANINE COMPOUND AND METHOD OF PREPARING THE SAME, COLOR FILTER CONTAINING PHTHALOCYANINE COMPOUND, AND COLORING COMPOSITION | DIC CORPORATION (JP) | 2017-11-16 | — | — | US | disclosed |
| US-6399642-B2 | TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-06-04 | — | — | US | disclosed |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-07-26 | — | — | US | disclosed |
| US-6221892-B1 | Heterocyclic topoisomerase poisons | THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS | 2001-04-24 | — | — | US | disclosed |
| EP-1054870-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6063801-A | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-4355030-A | Antiviral combinations | ELI LILLY AND COMPANY (US) | 1982-10-19 | — | — | US | disclosed |
| US-4289773-A | ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXOQUINOXALINE CARBOXYLATE AND A HINDERED AMINE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0029658-A1 | Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4271162-A | ETHYL 6,7-DICHLORO-3,4-DIHYDRO-3-ONOQUINOXALINE CARBOXYLATE AND 1-AMINOADAMANTANE | ELI LILLY AND COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| US-4264600-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0020836-A1 | Antiviral combinations | ELI LILLY AND COMPANY (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4210647-A | INFLUENZA VIRUS, ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXO-2-QUINOXALINECARBOXYLATE, 1-AMINOADAMANTANE | ELI LILLY AND COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
| EP-0010426-A1 | Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
| US-4185018-A | Process for producing benzofurazan-1-oxides | CIBA-GEIGY CORPORATION (US) | 1980-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | TOP1, TOP2A, TOP2B | ALDH1A1 2485/4885CYP3A4 1048/4885TDP1 4/4885 |
| US-20170327510-A1 | PHTHALOCYANINE COMPOUND AND METHOD OF PREPARING THE SAME, COLOR FILTER CONTAINING PHTHALOCYANINE COMPOUND, AND COLORING COMPOSITION | KMT5C, KMT5B, MAP1LC3C | ALDH1A1 3593/4885CYP3A4 3059/4885TDP1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.